What is the therapeutic effect of furosemide subcutaneous injection?

Furosemide subcutaneous injection (furosemide)-FUROSCIX, is a novel drug delivery formulation designed to treat patients with chronic heart failurewho suffer from congestion caused by fluid overload. The drug is administered via an intracorporeal syringe, providing patients with the convenience of self-administration at home. FUROSCIX is the first subcutaneous loop diuretic approved by the FDA, and its unique delivery method makes it an effective alternative to traditional intravenous injection.

In terms of therapeutic efficacy, furosemide subcutaneous injection is designed to provide similar bioavailability to intravenous injection. In a clinical study, furosemide subcutaneous injection showed extremely high bioavailability, reaching99.6%, which means that most of the drug can be effectively absorbed and exert its effects. In addition, the study also showed that after using furosemide subcutaneous injection, the patient's 8-hour urine output reached 2.7 liters, which is equivalent to patients receiving intravenous injection. This result shows that furosemide subcutaneous injection can effectively promote urine excretion, thereby relieving congestion symptoms and improving patients' quality of life.

Frusemide subcutaneous injection is particularly suitable for patients with New York Heart Associationchronic heart failure class II/III. In these patients, symptoms such as dyspnea, fatigue, and edema often occur due to the effects of fluid overload. Furosemide is administered subcutaneously, allowing patients to be treated in the comfort of their home environment, avoiding the inconvenience of frequent hospital visits and intravenous injections. This method not only improves patients' medication compliance, but also reduces the consumption of medical resources.

It should be noted that furosemide subcutaneous injection is not suitable for emergency situations or patients with acute pulmonary edema. Therefore, before using this medication, the physician must carefully evaluate the patient's specific condition to ensure its suitability. The administration limit of each furosemide subcutaneous injection is 80 mg and is completed within five hours through a pre-programmed disposable infusion set. This design ensures stable release and sustained effect of the drug.

Reference materials:https://www.drugs.com/newdrugs/fda-approves-furoscix-furosemide-home-congestion-due-fluid-overload-chronic-heart-failure-5916.html